WO1997019050A1 - Synthesis of carboxylic acid derivatives - Google Patents
Synthesis of carboxylic acid derivatives Download PDFInfo
- Publication number
- WO1997019050A1 WO1997019050A1 PCT/GB1996/002820 GB9602820W WO9719050A1 WO 1997019050 A1 WO1997019050 A1 WO 1997019050A1 GB 9602820 W GB9602820 W GB 9602820W WO 9719050 A1 WO9719050 A1 WO 9719050A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- formula
- carboxylic acid
- compound
- Prior art date
Links
- 0 CC(C)C[C@]([C@](C(O)=O)O)C(N(C)[C@](*)C(C)(C)C)=O Chemical compound CC(C)C[C@]([C@](C(O)=O)O)C(N(C)[C@](*)C(C)(C)C)=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
Definitions
- the present invention relates to a process for the preparation of biologically active carboxylic acid derivatives, especially matrix metalloproteinase inhibitors, and intermediates for such compounds
- MMPs matrix metalloproteinases
- rheumatoid arthritis a rheumatoid arthritis
- osteoarthritis a rheumatoid arthritis
- osteopenias such as osteoporosis
- pe ⁇ odontitis a rheumatoid arthritis
- gingivitis a rheumatoid arthritis
- corneal epidermal or gastric ulceration a cytokine tumour necrosis factor
- TNF cytokine tumour necrosis factor
- Metalloproteinases are characterised by the presence in the structure of a z ⁇ nc(ll) ionic site It is now known that there exists a range of metalloproteinase enzymes that includes fibroblast collagenase (Type 1 ), PMN-collagenase, 72 kDa-gelatmase, 92 kDa-gelatmase, stromelysin, stromelys ⁇ n-2 and PUMP- 1
- MMP inhibitors are peptide derivatives based on naturally occu ⁇ ng ammo acids, and are analogues of the cleavage site in the collagen molecule
- Other known MMP inhibitors are less peptidic in structure, and may more properly be viewed as pseudopeptides or peptide mimetics
- Such compounds usually have a functional group capable of binding to the zinc (II) site in the MMP, and known classes include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, and
- Z is the zinc binding hydroxamic acid (-CONHOH) or carboxylic acid (-COOH) group and the groups R, to R 5 are variable in accordance with the specific prior art disclosures of such compounds Examples of patent publications disclosing such structures are given below
- R is a (C r C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl(C C 6 )alkyl, phenyl(C r C 6 )alkoxy(C r C 6 )alkyl, phenoxy(C C 6 )alkyl, heteroaryl(C r C 6 )alkyl, heteroaryl(C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl, heteroaryloxy(C.-C 6 )alkyl, cycloalkyKC ⁇ C 6 )alkyl or cycloalkenyl(C 1 -C 6 ) alkyl group, any one of which may be optionally substituted by one or more substituents selected from (C 1 -C 6 )alkyl, 0(C r C 6 )alkyl, -S(C 1 -C)
- R 2 is the characterising group of a natural or non-natural ⁇ ammo acid in which any functional groups may be protected
- R 3 is hydrogen or a (C C 6 )alkyl group
- R 4 is hydrogen, (C r C 6 )alkyl, (C 1 -C 4 )perfluoroalkyl, a group D-(C C s alkyl)- wherem D represents hydroxy, (C 1 -C 6 )alkoxy, (C r C 6 )alkylth ⁇ o, acylamino, optionally substituted phenyl or heteroaryl, -NH 2 , or mono- or d ⁇ -(C r C 6 alkyl)am ⁇ no; or a phenyl or heteroaryl ring wherein any ring nitrogen atom may be oxidised as an N-oxide, which may be optionally fused to a benzene ring or to a heterocyclic ⁇ ng, and wherein any of the rings may be optionally substituted by
- X represents a carboxylic acid group or salt thereof, or a protected carboxylic acid group, which process comprises elimination of one of the groups X, and X 2 from a compound of formula (II)
- R 1 ? R 2 , R 3 , and R 4 are as defined above in relation to formula (I), and X 1 and X 2 each independently represent a carboxylic acid group or salt thereof, or a protected carboxylic acid group, the non-eliminated group X or X 2 corresponding to the group X in the desired compound of formula (I)
- the elimination of the group X, or X 2 from compound (II) may be effected by heating the compound of formula (II), preferably in a compatable liquid medium
- the temperature and time of the reaction is not generally critical, provided extreme conditions likely to degrade the reaction components are avoided In general reaction temperatures of from 20-60°C and reaction times of from 1-24 hours will be suitable
- the stereochemical configuration of the C atom carrying the R group in compound (II) is R, as shown
- the decarboxylation of (II) in accordance with the invention results in the end product (I) in which the C atom carrying the OH group has the S configuration as shown, as the predominant stereoisomer
- the compound of formula (II) used in the decarboxylation reaction according to the invention is preferably prepared by the reaction of a lactone of formula (III) with an amino acid derivative of formula (IV) or an acid addition salt thereof
- reaction of compounds (III) and (IV) may be carried out in a compatable solvent, preferably an aprotic solvent. If the amine (IV) is reacted as an acid addition salt, a base may be present in the reaction medium to neutralise the released acid.
- a compatable solvent preferably an aprotic solvent. If the amine (IV) is reacted as an acid addition salt, a base may be present in the reaction medium to neutralise the released acid.
- the temperature and time of the reaction is not generally critical, provided extreme conditions likely to degrade the reaction components or product are avoided. In general reaction temperatures of from 20-60°C and reaction times of from 1-24 hours will be suitable.
- (III) is R, as shown.
- (IV) is preferably S, since the preferred configuration of that C atom in the ultimate product (I) is also S.
- the configuration of that C atom is normally unaffected by the reaction of (IV) with (III), but if desired any resultant compound (II) in which that C atom is in the R configuration may be removed by differential solubility, or chromatographic techniques in the usual way.
- the groups X, X 1 and X 2 may be protected carboxylic acid groups. Carboxylic acid protecting groups are of course well known, eg from the art of peptide synthesis, and are discussed in the widely used handbook by T.W Greene and P. G.M.
- carboxylic acid protecting groups include allyl, tert-butyl, and benzyl, optionally substituted in the phenyl ring by one or more nitro or methoxy substituents, for example 4-methoxybenzyl or 2,4-d ⁇ methoxybe ⁇ zyl.
- carboxyiic acid protecting group it will be removable by acid or base hydrolysis, or by hydrogenation.
- (C r C 6 )alkyl or "lower alkyl” means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl.
- (C 2 -C 6 )alkenyl means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms at least one double bond of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, allyl, 1 - and 2-butenyl and 2-methyl-2-propenyl.
- cycloalkyl means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclohexyl, cyclooctyl, cycloheptyl, cyclopentyl, cyclobutyl and cyclopropyl
- cycloalkenyl means an unsaturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclohexenyl, cyclooctenyl, cycloheptenyl, cyclopentenyl, cyclobutenyl and cyclopropenyl In the case of cycloalkenyl rings of from 5-8 carbon atoms, the ring may contain more than one double bond
- heterocyclyl or “heterocyclic” means (i) a 5-7 membered heterocyclic ring containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzene ring, including for example, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl piperazinyl, indolyl, benzimidazolyl, maleimido, succmimido, phthalimido, 1 ,2-d ⁇ methyl-3,5-d ⁇ oxo-1 ,2,4-t ⁇ azol ⁇ d ⁇ n-4-yl, 3-methyl-2,5- d ⁇ oxo-1- ⁇ m ⁇ dazol ⁇ d ⁇ nyl and 34,4-tr ⁇ methyl-2,5
- heteroaryl means a 5-7 membered substituted or unsubstituted aromatic heterocyclic ring
- substituted as applied to any moiety herein means substituted with up to four substituents, each of which independently may be (C C 6 )alkyl, (C.-C 6 )alkoxy, hydroxy, mercapto, (C,- C 6 )alkylth ⁇ o, ammo, halo (including fluoro, chloro, bromo and iodo), nitro, trifiuoromethyl, -COOH, -CONH 2 , -CN, -COOR A or -CONHR A R A wherein R A is a (C C 6 )alkyl group or the residue of a natural alpha-ammo acid
- characterising group of an alpha-ammo acid means the characteristic side chain attached to the -CH(NH 2 )(COOH) moiety in an alpha-ammo acid
- Natural alpha-ammo acids include the following glycine, alanine, valine, leucine, isoleucine phenylalanine, tyrosine tryptophan, serine, threonine, cysteine, methionine, asparagme, glutamine lysine, histidine, arginine, glutamic acid and aspartic acid
- Natural alpha-ammo acids which contain functional substituents, for example ammo, carboxyl, hydroxy, mercapto, guanidyl, imidazolyl, or indolyl groups in their characteristic side chains include arginine, lysine, glutamic acid, aspartic acid, tryptophan, histidine, se ⁇ ne, threonine, tyrosine, and cysteine
- protected when used in relation to a functional substituent in a side chain of an alpha-ammo acid means a derivative of such a substituent which is substantially non-functional
- protected ammo groups include amido and acylamino
- protected hydroxy or mercapto groups include ethers and thioethers
- protected carboxyl groups include esters
- imidazolyl, indolyl or guanidyl groups may be protected as t-butoxycarbonyl derivatives
- the process and intermediates of the invention are useful for the preparation of compounds (I) which when X is a carboxylic acid group are MMP inhibitors, and when X is a protected carboxylic acid group can be deprotected to prepare the corresponding carboxylic acid MMP inhibitors
- compounds (I) wherein X is a carboxylic acid group can be converted by known methods to the corresponding hydroxamic acids, which are also MMP inhibitors
- the identity of the groups R,, R 2 , R 3 , and R 4 in compounds (II) and (III) will be selected according to the intended structure of the intended MMP inhibitor end product Those groups may therefore be chosen from amongst those found in the corresponding positions of known MMP inhibitors of analagous structure
- R may for example be n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyi, cyclohexylpropyl, phenylpropyl, 4-chlorophenylpropyl, 4-methylphenylpropyl, 4-methoxyphenylpropyl, phenylbutyl, propyloxymethyl and propylsuiphanyl, or in particular isobutyl,
- R 11 is -OH, -SH, halogen, (C 1 -C 4 )perfluoroalkyl, -CH 2 OH, -C0 2 H, - CO 2 (C 1 -C 6 )alkyl, optionally substituted phenyl or optionally substituted heteroaryl, -O(C r C 6 alkyl), -S(C r C 6 alkyl), -SO(C--C 6 alkyl), -SO 2 (C r C 6 alkyl), -OPh, -OCH 2 Ph, -SPh, -SOPh, -SO 2 Ph, -SCH 2 Ph, -SOCH 2 Ph, or -SO 2 CH 2 Ph, cyclohexylmethylsulphanyl, cyclohexylmethylsulphmyl, or cyclohexylmethylsulphonyl in which any of the foregoing Ph (phenyl) or cyclohexyl groups may be substituted, for example
- R 3 may for example be hydrogen or methyl
- R 4 may for example be hydrogen, ethyl, propyl, n-butyl, hydroxyethyl, hydroxypropyl, 2,2-d ⁇ methyl-3-hydroxypropyl, hydroxybutyl, methoxyethyl, ethoxyethyi, methoxypropyl, 2,2-d ⁇ methyl-3-methoxypropyl, 2,2-d ⁇ methyl-3- ethoxypropyl, 2-ethylth ⁇ oethyl, 2-acetoxyethyl, N-acetyl-ammoethyl, 3-(2- pyrrol ⁇ done)propyl, optionally substituted phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, or optionally substituted phenyl, napthyl, furanyl, thienyl, pyrro nyl, tetrahydrofuranyl, imidazolyl, oxadiazolyl
- the process of the invention is suitable for the preparation of compounds (I) wherein R, is isobutyl, R 2 is tert-butyl or 2-mercapto-2-methylpropyl, R 3 is hydrogen, and R 4 is methyl or 2-py ⁇ d ⁇ nyl, particularly such compounds wherein the C atom carrying the R 2 group is in the S configuration
- lactone (III) starting materials may be prepared by treating succinic acid derivatives of formula (V) with bromine, to form the lactone ring with elimination of HBr:
- amino acid derivative (IV) starting materials are either known compounds or are accessible by standard synthetic methods.
- N 1 -Benzyloxy-N 4-(2,2-d ⁇ methyl-1 S-methylcarbamoyl-propyl)-2S-hydroxy-3R- isobutyl-succinamide (8) (573 mg, 1 36 mmol) in ethanol (10mL) was treated with 10% palladium on carbon (57 mg, 10% by wt) and hydrogenated at room temperature and atmospheric pressure over 2 days.
- steps 3 and 4 (12) is converted to the MMP inhibitor 3R-[1 S-methylcarbamoyl-2-(4-naphthalen-1 -yl)-phenyl)-ethylcarbamoyl]-2S-hydroxy- 5-methyl-hexano ⁇ c acid, which in turn is converted by the methods of Example 1 steps 5 and 6 to the MMP Inhibitor 3R-[1 S-methylcarbamoyl-2-(4-naphthalen-1-yl)- phenyl)-ethylcarbamoyl]-2S-hydroxy-5-methyl-hexano-hydroxam ⁇ c ac ⁇ d
- steps 3 and 4 (10) is converted to the MMP inhibitor 3R-(2,2-D ⁇ methyl-1 S-py ⁇ d ⁇ n-2-ylcarbamoyl-propylcarbamoyl)-2S-hydroxy-5-methyl- hexanoic acid), which in turn is converted by the methods of Example 1 steps 5 and 6 to the MMP Inhibitor 3R-(2,2-D ⁇ methyl-1S-py ⁇ d ⁇ n-2-ylcarbamoyl-propylcarbamoyl)- 2S-hydroxy-5-methyl-hexano-hydroxam ⁇ c acid
- steps 3 and 4 (11) is converted to the MMP inhibitor 3R-t1 S-methylcarbamoyl-2-phenyl)-ethylcarbamoyl]-2S-hydroxy-5-methyl-hexanoic acid, which in turn is converted by the methods of Example 1 steps 5 and 6 to the MMP Inhibitor 3R-[1S-methylcarbamoyl-2-phenyl)-ethylcarbamoyl]-2S-hydroxy-5- methyl-hexano-hydroxamic acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96938374A EP0861226B1 (en) | 1995-11-18 | 1996-11-18 | Synthesis of carboxylic acid derivatives |
AU75823/96A AU7582396A (en) | 1995-11-18 | 1996-11-18 | Synthesis of carboxylic acid derivatives |
GB9806358A GB2321459A (en) | 1995-11-18 | 1996-11-18 | Synthesis of carboxylic acid derivatives |
US09/068,676 US5986132A (en) | 1995-11-18 | 1996-11-18 | Synthesis of carboxylic acid derivatives |
AT96938374T ATE189886T1 (en) | 1995-11-18 | 1996-11-18 | SYNTHESIS OF CARBOXIC ACID DERIVATIVES |
DE69606776T DE69606776T2 (en) | 1995-11-18 | 1996-11-18 | SYNTHESIS OF CARBONIC ACID DERIVATIVES |
JP9519481A JP2000500759A (en) | 1995-11-18 | 1996-11-18 | Production of carboxylic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523637.8A GB9523637D0 (en) | 1995-11-18 | 1995-11-18 | Synthesis of carboxylic acid derivatives |
GB9523637.8 | 1995-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997019050A1 true WO1997019050A1 (en) | 1997-05-29 |
Family
ID=10784104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002820 WO1997019050A1 (en) | 1995-11-18 | 1996-11-18 | Synthesis of carboxylic acid derivatives |
Country Status (9)
Country | Link |
---|---|
US (1) | US5986132A (en) |
EP (1) | EP0861226B1 (en) |
JP (1) | JP2000500759A (en) |
AT (1) | ATE189886T1 (en) |
AU (1) | AU7582396A (en) |
DE (1) | DE69606776T2 (en) |
ES (1) | ES2144271T3 (en) |
GB (2) | GB9523637D0 (en) |
WO (1) | WO1997019050A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074822B2 (en) | 2004-02-23 | 2006-07-11 | Solvay Pharmaceuticals Gmbh | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
ATE509956T1 (en) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | SPECIFIC PROTEASE INHIBITORS AND THEIR USE IN CANCER THERAPY |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002447A1 (en) * | 1992-07-23 | 1994-02-03 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as metalloproteinase inhibitors |
-
1995
- 1995-11-18 GB GBGB9523637.8A patent/GB9523637D0/en active Pending
-
1996
- 1996-11-18 ES ES96938374T patent/ES2144271T3/en not_active Expired - Lifetime
- 1996-11-18 JP JP9519481A patent/JP2000500759A/en active Pending
- 1996-11-18 AU AU75823/96A patent/AU7582396A/en not_active Abandoned
- 1996-11-18 US US09/068,676 patent/US5986132A/en not_active Expired - Fee Related
- 1996-11-18 AT AT96938374T patent/ATE189886T1/en active
- 1996-11-18 DE DE69606776T patent/DE69606776T2/en not_active Expired - Fee Related
- 1996-11-18 GB GB9806358A patent/GB2321459A/en not_active Withdrawn
- 1996-11-18 WO PCT/GB1996/002820 patent/WO1997019050A1/en active IP Right Grant
- 1996-11-18 EP EP96938374A patent/EP0861226B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002447A1 (en) * | 1992-07-23 | 1994-02-03 | British Biotech Pharmaceuticals Limited | Hydroxamic acid derivatives as metalloproteinase inhibitors |
Non-Patent Citations (2)
Title |
---|
AXEL GRIESBECK ET AL.: "Herstellung enantiomerenreiner Derivate von 3-Amino und 3-Mercaptobuttersäure durch SN2-Ringöffnung des beta-Lactons und eines 1,3-Dioxanons aus der 3-Hydroxybuttersäure", HELVETICA CHIMICA ACTA, vol. 70, 1987, BASEL CH, pages 1326 - 1332, XP000644375 * |
K. W. ROSENMUND ET AL.: "Synthesen in der Reihe der Anthelmintika", ARCHIV DER PHARMAZIE, vol. 287, no. 8, 1954, WEINHEIM, DE, pages 441 - 446, XP000617779 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074822B2 (en) | 2004-02-23 | 2006-07-11 | Solvay Pharmaceuticals Gmbh | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Also Published As
Publication number | Publication date |
---|---|
ATE189886T1 (en) | 2000-03-15 |
JP2000500759A (en) | 2000-01-25 |
GB9806358D0 (en) | 1998-05-20 |
US5986132A (en) | 1999-11-16 |
AU7582396A (en) | 1997-06-11 |
ES2144271T3 (en) | 2000-06-01 |
DE69606776T2 (en) | 2000-08-10 |
GB9523637D0 (en) | 1996-01-17 |
DE69606776D1 (en) | 2000-03-30 |
EP0861226B1 (en) | 2000-02-23 |
GB2321459A (en) | 1998-07-29 |
EP0861226A1 (en) | 1998-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101107896B1 (en) | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents | |
EP0754688B1 (en) | Dioxolane intermediates | |
US11434192B2 (en) | Process and intermediates | |
CN1610657A (en) | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof | |
JP2017526712A (en) | Methods for preparing astaxanthin esters | |
US6515134B1 (en) | Substituted acetylpridine derivatives and process for the preparation of intermediates for optically active beta-3 agonist by the use of the same | |
JP7138106B2 (en) | A novel method for the initial sacubitril intermediate | |
EP0861226B1 (en) | Synthesis of carboxylic acid derivatives | |
CN108148044B (en) | Amide compound and method for preparing Vonoprazan fumarate from same | |
KR100766578B1 (en) | A process for preparing rebamipide | |
JP3261503B2 (en) | Method for producing N-substituted glycine or glycine ester and application to indigo synthesis method | |
EP1599440A2 (en) | Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds | |
EP0874799B1 (en) | Preparation of allyl succinate derivatives and starting materials therefor | |
JP7373241B2 (en) | Method for producing pyrimidinyl bipyridine compounds and intermediates therefor | |
RU2374227C2 (en) | Method of producing intermediate products | |
JP5478508B2 (en) | Process for producing trans- {4-[(alkylamino) methyl] cyclohexyl} acetate | |
US6610855B2 (en) | Synthesis of 3-amino-3-aryl propanoates | |
JP2006063035A (en) | New method for esterifying carboxylic acids | |
JPH04124157A (en) | Production of optically active 4-chloro-3-hydroxybutanoic acid and its ester | |
JP2005154430A (en) | Method for producing pyrimidine derivative, intermediate for the same, and method for producing the intermediate | |
JP5167699B2 (en) | N-glucono-glutamic acid ester, method for producing the same, and intermediate thereof | |
JPH10273486A (en) | Production of 4-(2-alkenyl)-2,5-oxazolidinediones | |
JPS59148751A (en) | Synthesis of cyanoacetic ester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ GB HU IL JP KR MX NO NZ PL TR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996938374 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 519481 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09068676 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996938374 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996938374 Country of ref document: EP |